AEON Biopharma, Inc. (AEON)
| Market Cap | 249.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 24.05M |
| Shares Out | 38.12M |
| EPS (ttm) | 0.65 |
| PE Ratio | 10.06 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,384 |
| Open | 6.75 |
| Previous Close | 6.79 |
| Day's Range | 6.04 - 6.80 |
| 52-Week Range | 3.37 - 17.17 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+175.23%) |
| Earnings Date | May 11, 2024 |
About AEON
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AEON stock is "Strong Buy" and the 12-month stock price forecast is $18.0.
News
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first par...
AEON Biopharma Announces Redemption of Public Warrants
IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary ...
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine –
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine –
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
-- Termination of the Forward Purchase Agreements simplifies AEON's capitalization structure -- -- AEON to expand its Board of Directors with appointment of candidate selected by its strategic partner...
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
– Open label extension (OLE) Phase 2 data show peak efficacy for all ABP-450 doses and cycles in treating cervical dystonia (CD) occurred early, within 4 weeks; durability of effect was demonstrated 1...
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
– Expect to announce topline data in Q3 2024 – – Company plans in Q1 2024 an end-of-phase 2 meeting with the FDA to discuss the Phase 3 program in episodic migraine – – Anticipate shortening the open ...
AEON Biopharma Reports Third Quarter 2023 Financial Results
– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study –
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
– ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not me...
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary b...
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary b...
Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
The 7,380,394 AEON shares reflected in the Form 4 filed on August 14 th were transferred to limited partners of Strathspey Crown
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively.